Ginkgo Bioworks Financial Ratios
NYSE: DNAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
13.00+1.66 (+14.64%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ginkgo Bioworks ratio analysis
Ginkgo Bioworks earned a net margin of -183.8% in FY 2025, up from -240.9% a year earlier. Return on equity reached -61.5%, meaning Ginkgo Bioworks generated -0.61 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Ginkgo Bioworks financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Price / sales | 2.84 | 2.64 | 13.07 | 5.94 | 1,440.28 | — | — |
| Price / book | 0.95 | 0.84 | 3.00 | 1.63 | 300.27 | — | — |
| Operating margin | -185.3% | -246.5% | -343.8% | -462.4% | -582.6% | -178.8% | -132.1% |
| Net margin | -183.8% | -240.9% | -355.1% | -440.6% | -583.1% | -165.2% | -220.2% |
| Free cash flow margin | -105.0% | -168.3% | -133.7% | -63.7% | -98.9% | -252.6% | -123.4% |
| Return on equity (ROE) | -61.5% | -76.4% | -81.4% | -121.2% | -121.6% | -27.4% | -23.8% |
| Return on assets (ROA) | -27.9% | -39.7% | -53.6% | -82.9% | -88.4% | -18.8% | — |
| Current ratio | 4.92 | 5.62 | 6.11 | 8.38 | 12.79 | 5.83 | — |
| Revenue growth | -25.1% | -9.7% | -47.4% | 52.2% | 309.4% | 41.5% | — |